FDA Halts Regenxbio Gene Therapy Trial Again Over Safety Concerns
Source Summary
The FDA has placed a hold on a Regenxbio gene therapy trial following the emergence of new safety concerns. This marks another pause in the trial's progress.
Why it matters
Clinical trial holds by the FDA can significantly delay drug development and affect a company's ability to advance its therapeutic candidates.
What remains uncertain
The specific nature of the new safety concerns and the duration of the hold are not detailed in the source.
